Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Myasthenia Gravis × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 168 Observational 80 Expanded_access 1

Sponsor

Conditions

Neoplasms 32 Multiple Myeloma 29 Recurrence 28 Prostatic Neoplasms 25 Carcinoma, Non-Small-Cell Lung 25 Melanoma 20 Leukemia, Myeloid, Acute 18 Breast Neoplasms 16 Precursor Cell Lymphoblastic Leukemia-Lymphoma 15 Lymphoma 12 Sarcoma 11 Pancreatic Neoplasms 11 Neuroblastoma 11 Glioblastoma 11 Ovarian Neoplasms 9 Lymphoma, Large B-Cell, Diffuse 9 Colorectal Neoplasms 9 Carcinoma, Hepatocellular 9 Lung Neoplasms 8 Leukemia 8 Glioma 8 Small Cell Lung Carcinoma 7 Lymphoma, Non-Hodgkin 7 Lambert-Eaton Myasthenic Syndrome 7 Pheochromocytoma 6 Neoplasm Metastasis 6 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Cholangiocarcinoma 6 Carcinoma, Renal Cell 6

Interventions

efgartigimod alfa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04777734 2022-04-29

Efgartigimod Expanded Access for Generalized Myasthenia Gravis

argenx

Approved for marketing

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡